Abstract

Intracellular concentration of cGMP depends on the activity of guanylate cyclase, responsible for its synthesis, on the activity of cyclic nucleotide degrading enzymes – phosphodiesterases (PDEs). There are two forms of guanylate cyclase: the membrane-bound cyclase and the soluble form. The physiological activators of the membrane guanylate cyclase are natriuretic peptides (NPs), and of the cytosolic guanylate cyclase – nitric oxide (NO) and carbon monoxide (CO). Intracellular cGMP signaling pathways arise from its direct effect on the activity of G protein kinases, phosphodiesterases and cyclic nucleotide dependent cation channels. It has been shown in recent years that cGMP can also affect other signal pathways in cell signaling activity involving Wnt proteins and sex hormones. The increased interest in the research on the role of cGMP, resulted also in the discovery of its role in the regulation of phototransduction in the eye, neurotransmission, calcium homeostasis, platelet aggregation, heartbeat, bone remodeling, lipid metabolism and the activity of the cation channels. Better understanding of the mechanisms of action of cGMP in the regulation of cell function can create new opportunities for the cGMP affecting drugs use in the pharmacotherapy.

References

• 1. Andric S.A., Janjic M.M., Stojkov N.J., Kostic T.S.: Testosterone–induced modulation of nitric oxide-cGMP signaling pathway andandrogenesis in the rat Leydig cells. Biol. Reprod., 2010; 83: 434-442
  Google Scholar
• 2. Armani A., Marzolla V., Rosano G.M., Fabbri A., Caprio M.: Phosphodiesterasetype 5 (PDE5) in the adipocyte: a novel player in fatmetabolism?. Trends Endocrinol. Metab., 2011; 22: 404-411
  Google Scholar
• 3. Bender A.T., Beavo J.A.: Cyclic nucleotide phosphodiesterases:molecular regulation to clinical use. Pharmacol. Rev., 2006; 58: 488-520
  Google Scholar
• 4. Broillet M.C., Firestein S.: Cyclic nucleotide-gated channels. Molecularmechanisms of activation. Ann. NY Acad. Sci., 1999; 868:730-740
  Google Scholar
• 5. Budworth J., Meillerais S., Charles I., Powell K.: Tissue distributionof the human soluble guanylate cyclases. Biochem. Biophys.Res. Commun., 1999; 263: 696-701
  Google Scholar
• 6. Cai Y.L., Sun Q., Huang X., Jiang J.Z., Zhang M.H., Piao L.H., Jin Z.,Xu W.X.: cGMP-PDE3-cAMP signal pathway involved in the inhibitoryeffect of CNP on gastric motility in rat. Regul. Pept., 2013; 180: 43-49
  Google Scholar
• 7. Chrisman T.D., Garbers D.L., Parks M.A., Hardman J.G.: Characterizationof particulate and soluble guanylate cyclases from rat lung.J. Biol. Chem., 1975; 250: 374-381
  Google Scholar
• 8. Chusho H., Tamura N., Ogawa Y., Yasoda A., Suda M., MiyazawaT., Nakamura K., Nakao K., Kurihara T., Komatsu Y., Itoh H., TanakaK., Saito Y., Katsuki M., Nakao K.: Dwarfism and early death in micelacking C-type natriuretic peptide. Proc. Natl. Acad. Sci. USA, 2001;98: 4016-4021
  Google Scholar
• 9. Colombo G., Colombo M.D., Schiavon Lde L., d’Acampora A.J.:Phosphodiesterase 5 as target for adipose tissue disorders. NitricOxide, 2013; 35: 186-192
  Google Scholar
• 10. Coquil J.F., Franks D.J., Wells J.N., Dupuis M., Hamet P.: Characteristicsof a new binding protein distinct from the kinase forguanosine 3’:5’-monophosphate in rat platelets. Biochim. Biophys.Acta, 1980; 631: 148-165
  Google Scholar
• 11. Corbin J.D., Francis S.H.: Cyclic GMP phosphodiesterase-5: targetof sildenafil. J. Biol. Chem., 1999; 274: 13729-13732
  Google Scholar
• 12. Derbyshire E.R., Marletta M.A.: Biochemistry of soluble guanylatecyclase. Handb. Exp. Pharmacol., 2009; 191: 17-31
  Google Scholar
• 13. Dessì-Fulgheri P., Sarzani R., Rappelli A.: Role of the natriureticpeptide system in lipogenesis/lipolysis. Nutr. Metab. Cardiovasc. Dis.,2003; 13: 244-249
  Google Scholar
• 14. Fleming I., Busse R.: NO: the primary EDRF. J. Mol. Cell. Cardiol.,1999; 31: 5-14
  Google Scholar
• 15. Förstermann U., Boissel J.P., Kleinert H.: Expressional control ofthe ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOSIII). FASEB J., 1998; 12: 773-790
  Google Scholar
• 16. Francis S.H., Blount M.A., Corbin J.D.: Mammalian cyclic nucleotidephosphodiesterases: molecular mechanisms and physiologicalfunctions. Physiol. Rev., 2011; 91: 651-690
  Google Scholar
• 17. Francis S.H., Busch J.L, Corbin J.F., Sibley D.: cGMP-dependentprotein kinases and cGMP phosphodiesterases in nitric oxide andcGMP action. Pharmacol. Rev., 2010; 62: 525-563
  Google Scholar
• 18. Han S.J., Vaccari S., Nedachi T., Andersen C.B., Kovacina K.S.,Roth R.A., Conti M.: Protein kinase B/Akt phosphorylation of PDE3Aand its role in mammalian oocyte maturation. EMBO J., 2006; 25:5716-5725
  Google Scholar
• 19. Heydarpour P., Salehi-Sadaghiani M., Javadi-Paydar M., RahimianR., Fakhfouri G., Khosravi M., Khoshkish S., Gharedaghi M.H.,Ghasemi M., Dehpour A.R.: Estradiol reduces depressive-like behaviorthrough inhibiting nitric oxide/cyclic GMP pathway in ovariectomizedmice. Horm. Behav., 2013; 63: 361-369
  Google Scholar
• 20. Hofmann F., Bernhard D., Lukowski R., Weinmeister P.: cGMPregulated protein kinases (cGK). Handb. Exp. Pharmacol., 2009; 191:137-162
  Google Scholar
• 21. Hofmann F., Wegener J.W.: cGMP-dependent protein kinases(cGK). Methods Mol. Biol., 2013; 1020: 17-50
  Google Scholar
• 22. Hunter R.W., Mackintosh C., Hers I.: Protein kinase C-mediatedphosphorylation and activation of PDE3A regulate cAMP levels inhuman platelets. J. Biol. Chem., 2009; 284: 12339-12348
  Google Scholar
• 23. Jerczyńska H., Pawłowska Z.: Peptydy natriuretyczne – ich receptoryi rola w układzie krążenia. Postępy Biochem., 2008; 54: 35-42
  Google Scholar
• 24. Johnson M.L., Rajamannan N.: Diseases of Wnt signaling. Rev.Endocr. Metab. Disord., 2006; 7: 41-49
  Google Scholar
• 25. Kaupp U.B., Seifert R.: Cyclic nucleotide-gated ion channels.Physiol. Rev., 2002; 82: 769-824
  Google Scholar
• 26. Kimura H., Murad F.: Evidence for two different forms of guanylatecyclase in rat heart. J. Biol. Chem., 1974; 249: 6910-6916
  Google Scholar
• 27. Koesling D., Böhme E., Schultz G.: Guanylyl cyclases, a growingfamily of signal-transducing enzymes. FASEB J., 1991; 5: 2785-2791
  Google Scholar
• 28. Komiya Y., Habas R.: Wnt signal transduction pathways. Organogenesis,2008; 4: 68-75
  Google Scholar
• 29. Koziński K., Dobrzyń A.: Szlak sygnałowy Wnt i jego rola w regulacjimetabolizmu komórki. Postępy Hig. Med. Dośw., 2013; 67:1098-1108
  Google Scholar
• 30. Kuhn M.: Structure, regulation, and function of mammalianmembrane guanylyl cyclase receptors, with a focus on guanylylcyclase-A. Circ. Res., 2003; 93: 700-709
  Google Scholar
• 31. Kulkarni S.K., Dhir A.: Possible involvement of L-arginine-nitricoxide (NO)-cyclic guanosine monophosphate (cGMP) signalingpathway in the antidepressant activity of berberine chloride. Eur.J. Pharmacol., 2007; 569: 77-83
  Google Scholar
• 32. Levy F.O.: Cardiac PDEs and crosstalk between cAMP and cGMPsignalling pathways in the regulation of contractility. NaunynSchmiedebergs Arch. Pharmacol., 2013; 386: 665-670
  Google Scholar
• 33. Logan C.Y., Nusse R.: The Wnt signaling pathway in developmentand disease. Annu. Rev. Cell Dev. Biol., 2004; 20: 781-810
  Google Scholar
• 34. Lucas K.A., Pitari G.M., Kazerounian S., Ruiz-Stewart I., Park J.,Schulz S., Chepenik K.P., Waldman S.A.: Guanylyl cyclases and signalingby cyclic GMP. Pharmacol. Rev., 2000; 52: 375-414
  Google Scholar
• 35. Makuch E., Matuszyk J.: Fosfodiesterazy rodziny 3 sprzęgająszlaki sygnałowe zależne od kinaz białkowych i cyklicznego GMPz metabolizmem cyklicznego AMP. Postępy Hig. Med. Dośw., 2012;66: 492-500
  Google Scholar
• 36. Malinowski M., Biernat J., Roleder T., Dalecka A.M., Reszka B.,Deja M.A., Woś S., Gołba K.S.: Peptydy natriuretyczne: coś nowegow kardiologii? Kardiol. Pol., 2006; 64 (Suppl. 6): 578-585
  Google Scholar
• 37. Maurice D.H., Palmer D., Tilley D.G., Dunkerley H.A., NethertonS.J., Raymond D.R., Elbatany H.S., Jimmo S.L.: Cyclic nucleotidephosphodiesterase activity, expression, and targeting in cells of thecardiovascular system. Mol. Pharmacol., 2003; 64: 533-546
  Google Scholar
• 38. Mericq V., Uyeda J.A., Barnes K.M., De Luca F., Baron J.: Regulationof fetal rat bone growth by C-type natriuretic peptide andcGMP. Pediatr. Res., 2000; 47: 189-193
  Google Scholar
• 39. Michel T., Feron O.: Nitric oxide synthases: which, where, how,and why? J. Clin. Invest., 1997; 100: 2146-2152
  Google Scholar
• 40. Miyazawa T., Ogawa Y., Chusho H., Yasoda A., Tamura N., KomatsuY., Pfeifer A., Hofmann F., Nakao K.: Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediatedendochondral ossification. Endocrinology, 2002; 143: 3604-3610
  Google Scholar
• 41. Moffatt P., Thomas G., Sellin K., Bessette M.C., Lafreniere F.,Akhouayri O., St-Arnaud R., Lanctot C.: Osteocrin is a specific ligandof the natriuretic peptide clearance receptor that modulates bonegrowth. J. Biol. Chem., 2007; 282: 36454-36462
  Google Scholar
• 42. Nossaman B., Pankey E., Kadowitz P.: Stimulators and activatorsof soluble guanylate cyclase: review and potential therapeutic indications.Crit. Care Res. Pract., 2012; 2012: 290805
  Google Scholar
• 43. Ørstavik S., Natarajan V., Taskén K., Jahnsen T., Sandberg M.:Characterization of the human gene encoding the type Iα and typeIβ cGMP-dependent protein kinase (PRKG1). Genomics, 1997; 42:311-318
  Google Scholar
• 44. Pakuła D., Marek B., Kajdaniuk D., Kos-Kudła B., Borgiel-MarekH., Krysiak R., Gatnar A., Pakuła P.: Peptydy natriuretyczne: ich znaczeniew diagnostyce i terapii. Endokrynol. Pol., 2007; 58: 364-374
  Google Scholar
• 45. Palmer D., Jimmo S.L., Raymond D.R., Wilson L.S., Carter R.L.,Maurice D.H.: Protein kinase A phosphorylation of human phosphodiesterase3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzedinactivation. J. Biol. Chem., 2007; 282: 9411-9419
  Google Scholar
• 46. Pfeifer A., Kilić A., Hoffmann L.S.: Regulation of metabolismby cGMP. Pharmacol. Ther., 2013; 140: 81-91
  Google Scholar
• 47. Pifferi S., Boccaccio A., Menini A.: Cyclic nucleotide-gated ionchannels in sensory transduction. FEBS Lett., 2006; 580: 2853-2859
  Google Scholar
• 48. Pimentel E.: Handbook of Growth Factors, vol. 1, CRC Press,1994, 106-107
  Google Scholar
• 49. Potter L.R., Abbey-Hosch S., Dickey D.M.: Natriuretic peptides,their receptors, and cyclic guanosine monophosphate-dependentsignaling functions. Endocr. Rev., 2006; 27: 47-72
  Google Scholar
• 50. Potthast R., Potter L.R.: Phosphorylation-dependent regulationof the guanylyl cyclase-linked natriuretic peptide receptors. Peptides,2005; 26: 1001-1008
  Google Scholar
• 51. Qvigstad E., Moltzau L.R., Aronsen J.M., Nguyen C.H., HougenK., Sjaastad I., Levy F.O., Skomedal T., Osnes J.B.: Natriuretic peptidesincrease β1-adrenoceptor signalling in failing hearts throughphosphodiesterase 3 inhibition. Cardiovasc. Res., 2010; 85: 763-772
  Google Scholar
• 52. Rybalkin S.D., Yan C., Bornfeld K.E., Beavo J.A.: Cyclic GMP phosphodiesterasesand regulation of smooth muscle function. Circ.Res., 2003; 93: 280-291
  Google Scholar
• 53. Sengenès C., Berlan M., De Glisezinski I., Lafontan M., Galitzky J.:Natriuretic peptides: a new lipolytic pathway in human adipocytes.FASEB J., 2000; 14: 1345-1351
  Google Scholar
• 54. Sengenes C., Stich V., Berlan M., Hejnova J., Lafontan M., PariskovaZ., Galitzky J.: Increased lipolysis in adipose tissue and lipidmobilization to natriuretic peptides during low-calorie diet in obesewomen. Int. J. Obes. Relat. Metab. Disord., 2002; 26: 24-32
  Google Scholar
• 55. Shimizu N., Kawakami K., Ishitani T.: Visualization and explorationof Tcf/Lef function using a highly responsive Wnt/β-cateninsignaling-reporter transgenic zebrafish. Dev. Biol., 2012; 370: 71-85
  Google Scholar
• 56. Springer J., Azer J., Hua R., Robbins C., Adamczyk A., McBoyle S., Bissell M.B., Rose R.A.: The natriuretic peptides BNP and CNPincrease heart rate and electrical conduction by stimulating ioniccurrents in the sinoatrial node and atrial myocardium following activationof guanylyl cyclase-linked natriuretic peptide receptors. J.Mol. Cell. Cardiol., 2012; 52: 1122-1134
  Google Scholar
• 57. Surks H.K.: cGMP-dependent protein kinase I and smooth musclerelaxation: a tale of two isoforms. Circ. Res., 2007; 101: 1078-1080
  Google Scholar
• 58. Thomas G., Moffatt P., Salois P., Gaumond M.H., Gingras R., GodinE., Miao D., Goltzman D., Lanctot C.: Osteocrin, a novel bone-specificsecreted protein that modulates the osteoblast phenotype. J. Biol.Chem., 2003; 278: 50563-50571
  Google Scholar
• 59. Wang H., Lee Y., Malbon C.C.: PDE6 is an effector for the Wnt/Ca2+/cGMP-signalling pathway in development. Biochem. Soc.Trans., 2004; 32: 792-796
  Google Scholar
• 60. Wang Y., Li Y.P., Paulson C., Shao J.Z., Zhang X., Wu M., ChenW.: Wnt and the Wnt signaling pathway in bone development anddisease. Front Biosci., 2014; 19: 379-407
  Google Scholar
• 61. Wolanin P.M., Thomason P.A., Stock J.B.: Histidine protein kinases:key signal transducers outside the animal kingdom. GenomeBiol., 2002; 3: reviews3013.1
  Google Scholar
• 62. Yallampalli C., Byam-Smith M., Nelson S.O., Garfield R.E.: Steroidhormones modulate the production of nitric oxide and cGMP in therat uterus. Endocrinology, 1994; 134: 1971-1974
  Google Scholar
• 63. Yallampalli C., Dong Y.L.: Estradiol-17β inhibits nitric oxidesynthase (NOS)-II and stimulates NOS-III gene expression in the ratuterus. Biol. Reprod., 2000; 63: 34-41
  Google Scholar
• 64. Zielniok K., Gajewska M., Motyl T.: Molekularne aspekty działania17β-estradiolu i progesteronu w komórkowych szlakach sygna-łowych. Postępy Hig. Med. Dośw., 2014; 68: 777-792
  Google Scholar

Full text